New hope for kids with tough liver cancer: immune therapy trial opens
NCT ID NCT04134559
Summary
This study is testing whether an immunotherapy drug called pembrolizumab (KEYTRUDA®) can help control liver cancer that has come back or hasn't responded to other treatments in children and young adults. The trial will enroll up to 18 participants under age 30 to see if the drug can stop or shrink tumors. Researchers will also study tumor samples to learn why the treatment might work for some patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital Boston
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact
-
Cincinnati Children's Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
Contact
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.